Version 1
: Received: 24 September 2024 / Approved: 25 September 2024 / Online: 25 September 2024 (17:02:43 CEST)
How to cite:
Panagiotidis, E.; Zhang-Yin, J. T. The Role of PET/CT in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives. Preprints2024, 2024092036. https://doi.org/10.20944/preprints202409.2036.v1
Panagiotidis, E.; Zhang-Yin, J. T. The Role of PET/CT in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives. Preprints 2024, 2024092036. https://doi.org/10.20944/preprints202409.2036.v1
Panagiotidis, E.; Zhang-Yin, J. T. The Role of PET/CT in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives. Preprints2024, 2024092036. https://doi.org/10.20944/preprints202409.2036.v1
APA Style
Panagiotidis, E., & Zhang-Yin, J. T. (2024). The Role of PET/CT in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives. Preprints. https://doi.org/10.20944/preprints202409.2036.v1
Chicago/Turabian Style
Panagiotidis, E. and Jules Tianyu Zhang-Yin. 2024 "The Role of PET/CT in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives" Preprints. https://doi.org/10.20944/preprints202409.2036.v1
Abstract
Differentiated thyroid cancer (DTC), comprising papillary and follicular thyroid carcinoma, is the most common thyroid malignancy and typically has a favourable prognosis when detected early. Positron emission tomography/computed tomography (PET/CT) has emerged as a valuable imaging modality, integrating metabolic and anatomical data. Although PET/CT is not usually part of the initial diagnostic process due to DTC's indolent nature and low metabolic activity, it plays an essential role in selected clinical scenarios. This includes identifying recurrence in patients with elevated thyroglobulin (Tg) levels and negative radioactive iodine (RAI) scans, evaluating metastatic disease, and guiding treatment in advanced cases. As the use of PET/CT evolves in oncology, this review explores its application in the staging, detection of recurrence, follow-up, and future challenges in managing DTC. The review also considers emerging radiotracers and the theragnostic potential of PET/CT.
Keywords
thyroid cancer; PET/CT
Subject
Medicine and Pharmacology, Endocrinology and Metabolism
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
